drugset
drugset / Trial / NCT01884688

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

NCT01884688 ↗

Phase 2 Completed 3 enrolled University of Arkansas Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine the safety and in vivo persistence and expansion of autologous and expansion of autologous, ex vivo expanded-natural killer(ENK) cells.

Timeline

Start
2013-04
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ENK Cell Infusion Cell therapy — —
Background aldesleukin Protein / enzyme biologic 30 iu —

Indications

plasma cell myeloma